Alligator Bioscience AB (publ)

Hello and welcome to Alligator Biosciences 2025 year-end report call. My name is Greta Hög. I am the IR and Communications Manager at Alligator and I will be introducing today's call. With me are our CEO Søren Reinholt and our CFO Johan Gilius. They will walk you through the latest developments from the previous quarter and the year. as well as the upcoming news flow. After this, they will be happy to take any questions you may have. You can post them in the Q&A function of this webinar, or you can send them by email to ir at alligatorbioscience.com. As you know, Alligator Bioscience is a publicly listed company, and I'd like to note that today's presentation may include forward-looking statements. Please refer to the disclaimer on this slide, which applies to the full presentation. With the formalities out of the way, I'm handing this over to you, Sarah.

Thank you, Greta, and it's a pleasure to welcome you all to this Q4 or end-year report call in alligator bioscience. What we will do today is go through some of the events of the fourth quarter, of course, and we will focus primarily on mitocelular map. And I'll also provide you some information about our partner program, HLX22. So Greta, if I could get the next slide just to get going. What has happened sort of on the high lines in the company, we have published two exciting papers, very exciting papers on metazolumab. all the biomarker data from the phase 2 study and we were published in cell reports and also data from the reactive 2 study which was an investigator-initiated study also in pancreatic cancer where we combined metazolamab with chemotherapy and also with a dendritic cell vaccine that was published in Nature Communications. And I'm of course not mentioning these two publications just for the sake of it, but of course to highlight the underlying strong data, both clinically and also mechanistically, and I'll share a little bit with you in just a few seconds. In addition, we have completed a rights issue of around 91 million in gross proceeds and as part of that, there is a number of outstanding warrants in the series TO14 and Johan will talk more about that later during the call. On the general portfolio, we further strengthened the IP position of yet another US patent approval on our bispecific molecule 804066, so the CD40-CCAM5 bispecific antibody. And then on the HLX molecule, HLX22, Henleus received the regulatory approval in China for their phase 2-3 trials in HER2-positive breast cancer.

And we'll talk more about those in just a second. If we go to the next slide, guys.